Heart Failure with Preserved Ejection Fraction: What Is in a Name?

Cardiology in Review

Volumn 23, Issue 4, 2015, Pages 161-167

  Jumean, Marwan F ^a   Konstam, Marvin A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diastolic function; elderly; heart failure; heart failure with preserved ejection fraction; HFpEF; metabolic heart failure; metabolic syndrome; senile heart failure

Indexed keywords

COLLAGEN;

AGING; CARDIAC PATIENT; CARDIORENAL SYNDROME; CLINICAL TRIAL (TOPIC); COLLAGEN METABOLISM; DIASTOLE; DIASTOLIC DYSFUNCTION; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; INFLAMMATION; METABOLIC HEART FAILURE; METABOLIC SYNDROME X; MUSCLE CELL; MUSCLE HYPERTROPHY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLE; DISEASE MANAGEMENT; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; PHYSIOLOGY;

DISEASE MANAGEMENT; HEART FAILURE; HUMANS; PROGNOSIS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84936764437     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000057     Document Type: Review

References (91)

1. Hammermeister KE, Kennedy JW. Predictors of surgical mortality in patients undergoing direct myocardial revascularization. Circulation. 1974;50(2 Suppl):II112-II115.
2. Cohn PF, Gorlin R, Cohn LH, et al. Left ventricular ejection fraction as a prognostic guide in surgical treatment of coronary and valvular heart disease. Am J Cardiol. 1974;34:136-141.
3. Nelson GR, Cohn PF, Gorlin R. Prognosis in medically-treated coronary artery disease: influence of ejection fraction compared to other parameters. Circulation. 1975;52:408-412.
4. Eaton LW, Weiss JL, Bulkley BH, et al. Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography. N Engl J Med. 1979;300:57-62.
5. Mitchell GF, Lamas GA, Vaughan DE, et al. Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol. 1992;19:1136-1144.
6. McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation. 1986;74:693-702.
7. Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. 1997;30:1527-1533.
8. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10:165-193.
9. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539-2550.
10. Petrie MC, Caruana L, Berry C, et al. "Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction? Heart. 2002;87:29-31.
11. Yu CM, Lin H, Yang H, et al. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation. 2002;105:1195-1201.
12. Yip G, Wang M, Zhang Y, et al. Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart. 2002;87:121-125.
13. Grossman W, McLaurin LP, Rolett EL. Alterations in left ventricular relaxation and diastolic compliance in congestive cardiomyopathy. Cardiovasc Res. 1979;13:514-522.
14. Grossman W. Diastolic dysfunction and congestive heart failure. Circulation. 1990;81(2 Suppl):III1-III7.
15. Morgan JP, Erny RE, Allen PD, et al. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation. 1990;81(2 Suppl):III21-III32.
16. Piacentino V 3rd, Weber CR, Chen X, et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res. 2003;92:651-658.
17. Luo M, Anderson ME. Mechanisms of altered Ca2+ handling in heart failure. Circ Res. 2013;113:690-708.
18. Konstam MA, Kramer DG, Patel AR, et al. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4:98-108.
19. Yancy CW, Jessup M, Bozkurt B, et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-e239.
20. Maisel AS, McCord J, Nowak RM, et al.; Breathing Not Properly Multinational Study Investigators. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003;41:2010-2017.
21. Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006;12:10-38.
22. Morris AA, Butler J, Konstam MA. Heart failure with normal ejection fraction, heart failure with preserved ejection fraction, diastolic heart failure, or huff-puff: time for a new taxonomy for hypertensive-metabolic heart failure. J Card Fail. 2014;20:779-781.
23. Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588-595.
24. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
25. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA. 2006;296:2209-2216.
26. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387-1393.
27. McMurray JJ, Carson PE, Komajda M, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008;10:149-156.
28. Fonarow GC, Stough WG, Abraham WT, et al.; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50:768-777.
29. Yancy CW, Lopatin M, Stevenson LW, et al.; ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and inhospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47:76-84.
30. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137:631-639.
31. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011;4:27-35.
32. Zile MR, Gottdiener JS, Hetzel SJ, et al.; I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011;124:2491-2501.
33. Persson H, Lonn E, Edner M, et al.; Investigators of the CHARM Echocardiographic Substudy-CHARMES. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol. 2007;49:687-694.
34. Kasner M, Westermann D, Lopez B, et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol. 2011;57:977-985.
35. Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011;4:44-52.
36. Borbély A, van der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774-781.
37. Kitzman DW. Diastolic dysfunction in the elderly. Genesis and diagnostic and therapeutic implications. Cardiol Clin. 2000;18:597-617, x.
38. Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001;104:779-782.
39. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101:2118-2121.
40. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503-1508.
41. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-Abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953-1959.
42. Selby DE, Palmer BM, LeWinter MM, et al. Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J Am Coll Cardiol. 2011;58:147-154.
43. Chaturvedi RR, Herron T, Simmons R, et al. Passive stiffness of myocardium from congenital heart disease and implications for diastole. Circulation. 2010;121:979-988.
44. van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830-839.
45. van Heerebeek L, Borbély A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966-1973.
46. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271.
47. Matsubara J, Sugiyama S, Nozaki T, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol. 2011;57:861-869.
48. Shah KB, Kop WJ, Christenson RH, et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem. 2011;57:874-882.
49. Collier P, Watson CJ, Voon V, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail. 2011;13:1087-1095.
50. Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al.; Health ABC Study Investigators. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55:2129-2137.
51. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998;101:812-818.
52. Zannad F, Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev. 2005;10:71-78.
53. González A, Ravassa S, Beaumont J, et al. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol. 2011;58:1833-1843.
54. López B, González A, Díez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010;121:1645-1654.
55. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87:1285-1342.
56. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568-575.
57. Weber KT, Sun Y, Tyagi SC, et al. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol. 1994;26:279-292.
58. Redfield MM, Jacobsen SJ, Borlaug BA, et al. Age-And gender-related ventricularvascular stiffening: a community-based study. Circulation. 2005;112:2254-2262.
59. Loffredo FS, Nikolova AP, Pancoast JR, et al. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res. 2014;115:97-107.
60. Kitzman DW, Higginbotham MB, Cobb FR, et al. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol. 1991;17:1065-1072.
61. Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricularvascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982-1990.
62. Melenovsky V, Borlaug BA, Rosen B, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198-207.
63. Chen CH, Nakayama M, Nevo E, et al. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol. 1998;32:1221-1227.
64. Kawaguchi M, Hay I, Fetics B, et al. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714-720.
65. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010;121:2592-2600.
66. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527-1539.
67. McAlister FA, Ezekowitz J, Tarantini L, et al.; Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) Investigators. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail. 2012;5:309-314.
68. Kiernan M, Rossignol P, Sarnak MJ, et al. Early and late effects of angiotensin receptor blockade on kidney function in patients with chronic heart failure. J Am Coll Cardiol 2012;59:E1040.
69. Konstam MA. Renal function and heart failure treatment: when is a loss really a gain? Circ Heart Fail. 2011;4:677-679.
70. Blair JE, Pang PS, Schrier RW, et al.; EVEREST Investigators. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011;32:2563-2572.
71. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955-962.
72. Pan M, Zhu JH, Liu ZH, et al. Angiotensin-converting enzyme gene 2350 G/A polymorphism is associated with left ventricular hypertrophy but not essential hypertension. Hypertens Res. 2007;30:31-37.
73. Cannella G, Paoletti E, Delfino R, et al. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis. 1997;30:659-664.
74. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32:865-879.
75. Ramires FJ, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol. 1998;30:475-483.
76. McEwan PE, Gray GA, Sherry L, et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation. 1998;98:2765-2773.
77. Cleland JG, Tendera M, Adamus J, et al.; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345.
78. Yusuf S, Pfeffer MA, Swedberg K, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362:777-781.
79. Massie BM, Carson PE, McMurray JJ, et al.; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467.
80. Weber KT, Brilla CG, Campbell SE, et al. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol. 1993;88(Suppl 1):107-124.
81. Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology. 2004;145:3153-3157.
82. Lacolley P, Safar ME, Lucet B, et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol. 2001;37:662-667.
83. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-Angiotensin-Aldosterone system. Circulation. 1991;83:1849-1865.
84. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res. 1994;28:1863-1867.
85. Pfeffer MA, Pitt B, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;371:181-182.
86. Redfield MM, Chen HH, Borlaug BA, et al.; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277.
87. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
88. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
89. Dahlöf B, Devereux RB, Kjeldsen SE, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
90. Klingbeil AU, Schneider M, Martus P, et al. A meta-Analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
91. Zreikat HH, Harpe SE, Slattum PW, et al. Effect of renin angiotensin system inhibition on cardiovascular events in older hypertensive patients with metabolic syndrome. Metabolism. 2014;63:392-399.